ZIOPHARM Oncology Company Profile (NASDAQ:ZIOP)

About ZIOPHARM Oncology (NASDAQ:ZIOP)

ZIOPHARM Oncology logoZIOPHARM Oncology, Inc. is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease. It has developed an adenoviral vector, Ad-RTS-IL-12, which is administered intra-tumorally under the control of the RheoSwitch Therapeutic System (RTS) expression platform. Its initial clinical stage product candidate, which is being developed using the immuno-oncology platform is Ad-RTS-IL-12 + veledimex. Ad-RTS-IL-12 + veledimex uses its gene delivery system to produce interleukin-12. As of December 31, 2016, it had completed two Phase II studies evaluating Ad-RTS-IL-12 + veledimex, for the treatment of metastatic melanoma and metastatic breast cancer.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:ZIOP
  • CUSIP: 98973P10
  • Web: www.ziopharm.com
Capitalization:
  • Market Cap: $810.61 million
  • Outstanding Shares: 140,632,000
Average Prices:
  • 50 Day Moving Avg: $6.18
  • 200 Day Moving Avg: $6.22
  • 52 Week Range: $4.84 - $7.88
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -9.91
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $6.39 million
  • Price / Sales: 126.55
  • Book Value: ($0.46) per share
  • Price / Book: -12.50
Profitability:
  • EBITDA: ($48,700,000.00)
  • Net Margins: -789.28%
  • Return on Assets: -45.35%
Debt:
  • Current Ratio: 7.83%
  • Quick Ratio: 7.83%
Misc:
  • Average Volume: 1.05 million shs.
  • Beta: 1.64
  • Short Ratio: 42.97
 

Frequently Asked Questions for ZIOPHARM Oncology (NASDAQ:ZIOP)

What is ZIOPHARM Oncology's stock symbol?

ZIOPHARM Oncology trades on the NASDAQ under the ticker symbol "ZIOP."

How were ZIOPHARM Oncology's earnings last quarter?

ZIOPHARM Oncology Inc (NASDAQ:ZIOP) posted its quarterly earnings results on Monday, July, 31st. The company reported ($0.13) earnings per share for the quarter, hitting the consensus estimate of ($0.13). The firm had revenue of $1.60 million for the quarter, compared to the consensus estimate of $1.66 million. The firm's revenue was down 5.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.01) EPS. View ZIOPHARM Oncology's Earnings History.

When will ZIOPHARM Oncology make its next earnings announcement?

ZIOPHARM Oncology is scheduled to release their next quarterly earnings announcement on Wednesday, November, 8th 2017. View Earnings Estimates for ZIOPHARM Oncology.

Where is ZIOPHARM Oncology's stock going? Where will ZIOPHARM Oncology's stock price be in 2017?

3 brokers have issued 12 month price objectives for ZIOPHARM Oncology's stock. Their forecasts range from $10.00 to $23.00. On average, they expect ZIOPHARM Oncology's share price to reach $16.50 in the next twelve months. View Analyst Ratings for ZIOPHARM Oncology.

Are investors shorting ZIOPHARM Oncology?

ZIOPHARM Oncology saw a increase in short interest in September. As of September 29th, there was short interest totalling 33,322,518 shares, an increase of 2.7% from the September 15th total of 34,255,870 shares. Based on an average daily volume of 968,494 shares, the days-to-cover ratio is currently 34.4 days. Approximately 26.1% of the shares of the stock are short sold.

Who are some of ZIOPHARM Oncology's key competitors?

Who are ZIOPHARM Oncology's key executives?

ZIOPHARM Oncology's management team includes the folowing people:

  • Laurence James Neil Cooper M.D., Ph.D., Chief Executive Officer
  • Kevin G. Lafond CPA, Principal Financial Officer, Chief Accounting Officer, Vice President - Finance, Treasurer
  • Caesar J. Belbel, Chief Operating Officer, Executive Vice President, Chief Legal Officer, Secretary
  • Francois Lebel M.D., Executive Vice President - Research and Development and Chief Medical Officer
  • David M. Mauney M.D., Executive Vice President, Chief Business Officer
  • Lynn Ferrucci, Senior Vice President - Human Resources, Facilities and Administration
  • David Connolly, Vice President - Corporate Communications and Investor Relations
  • Murray Brennan M.D., Non-Executive Lead Independent Director
  • Randal J. Kirk, Director
  • James A. Cannon, Independent Director

How do I buy ZIOPHARM Oncology stock?

Shares of ZIOPHARM Oncology can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ZIOPHARM Oncology's stock price today?

One share of ZIOPHARM Oncology stock can currently be purchased for approximately $5.75.


MarketBeat Community Rating for ZIOPHARM Oncology (NASDAQ ZIOP)
Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  165 (Vote Outperform)
Underperform Votes:  198 (Vote Underperform)
Total Votes:  363
MarketBeat's community ratings are surveys of what our community members think about ZIOPHARM Oncology and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for ZIOPHARM Oncology (NASDAQ:ZIOP) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 2 Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $16.50 (186.96% upside)
Consensus Price Target History for ZIOPHARM Oncology (NASDAQ:ZIOP)
Price Target History for ZIOPHARM Oncology (NASDAQ:ZIOP)
Analysts' Ratings History for ZIOPHARM Oncology (NASDAQ:ZIOP)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/1/2017HC WainwrightSet Price TargetBuy$10.00MediumView Rating Details
2/28/2017Griffin SecuritiesReiterated RatingBuy$23.00N/AView Rating Details
1/12/2017J P Morgan Chase & CoReiterated RatingHoldN/AView Rating Details
8/10/2016Wells Fargo & CompanyUpgradeUnderperform -> Market PerformN/AView Rating Details
7/18/2016MizuhoReiterated RatingNeutral$7.00 -> $5.00N/AView Rating Details
6/2/2016Raymond James Financial, Inc.Initiated CoverageMarket PerformN/AView Rating Details
(Data available from 10/19/2015 forward)

Earnings

Earnings History for ZIOPHARM Oncology (NASDAQ:ZIOP)
Earnings by Quarter for ZIOPHARM Oncology (NASDAQ:ZIOP)
Earnings History by Quarter for ZIOPHARM Oncology (NASDAQ ZIOP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017        
7/31/2017Q2 2017($0.13)($0.13)$1.66 million$1.60 millionViewN/AView Earnings Details
5/1/2017Q1 2017($0.12)($0.15)$1.71 million$1.60 millionViewListenView Earnings Details
11/9/2016Q3 2016($0.11)($0.11)$1.45 million$1.60 millionViewN/AView Earnings Details
8/9/2016Q216($0.11)($1.01)$1.52 million$1.70 millionViewN/AView Earnings Details
5/10/2016Q1($0.08)($0.09)$1.89 million$1.97 millionViewN/AView Earnings Details
2/24/2016Q4($0.07)($0.07)$1.82 million$1.92 millionViewN/AView Earnings Details
11/2/2015Q315($0.13)($0.14)$1.19 million$1.90 millionViewN/AView Earnings Details
8/10/2015Q2($0.22)($0.11)$57.70 million$0.27 millionViewN/AView Earnings Details
5/7/2015($0.13)($0.10)$0.20 million$0.30 millionViewN/AView Earnings Details
2/26/2015Q414($0.14)($0.09)$420.00 million$0.34 millionViewN/AView Earnings Details
10/30/2014Q314($0.12)($0.06)$0.20 million$0.63 millionViewN/AView Earnings Details
8/7/2014Q214($0.17)($0.06)$7.50 million$0.20 millionViewN/AView Earnings Details
5/8/2014Q114($0.10)($0.10)$0.20 million$0.20 millionViewN/AView Earnings Details
3/3/2014Q413($0.15)($0.09)$0.20 million$0.20 millionViewN/AView Earnings Details
10/22/2013Q313($0.17)($0.20)$0.20 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.24)($0.22)$0.20 million$0.20 millionViewN/AView Earnings Details
3/18/2013Q4 2012($0.29)($0.48)$0.17 million$0.20 millionViewN/AView Earnings Details
11/8/2012Q312($0.28)($0.28)$0.20 million$0.20 millionViewN/AView Earnings Details
8/2/2012($0.23)($0.29)ViewN/AView Earnings Details
5/3/2012($0.22)($0.25)ViewN/AView Earnings Details
2/29/2012($0.23)($0.24)ViewN/AView Earnings Details
11/3/2011($0.28)($0.01)ViewN/AView Earnings Details
8/1/2011($0.23)($0.16)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for ZIOPHARM Oncology (NASDAQ:ZIOP)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.09)($0.09)($0.09)
Q2 20171($0.11)($0.11)($0.11)
Q3 20171($0.09)($0.09)($0.09)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for ZIOPHARM Oncology (NASDAQ:ZIOP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for ZIOPHARM Oncology (NASDAQ:ZIOP)
Insider Ownership Percentage: 10.40%
Institutional Ownership Percentage: 41.94%
Insider Trades by Quarter for ZIOPHARM Oncology (NASDAQ:ZIOP)
Institutional Ownership by Quarter for ZIOPHARM Oncology (NASDAQ:ZIOP)
Insider Trades by Quarter for ZIOPHARM Oncology (NASDAQ:ZIOP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/4/2015Murray BrennanDirectorSell40,000$9.70$388,000.00View SEC Filing  
2/9/2015Randal J KirkDirectorBuy1,440,000$8.75$12,600,000.00View SEC Filing  
10/29/2013Randal J KirkDirectorBuy2,857,143$3.50$10,000,000.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for ZIOPHARM Oncology (NASDAQ:ZIOP)
Latest Headlines for ZIOPHARM Oncology (NASDAQ:ZIOP)
Source:
DateHeadline
fool.com logoThe case for Ziopharm Oncology, Inc. - Motley Fool
www.fool.com - October 18 at 11:02 AM
globenewswire.com logoZIOPHARM Oncology Announces First Patient Dosed in New Phase 1 Study of Ad-RTS-hIL-12 plus Veledimex for the ... - GlobeNewswire (press release)
globenewswire.com - October 17 at 9:32 AM
benzinga.com logoWatch These 8 Huge Put Purchases In Friday Trade - Benzinga
www.benzinga.com - October 13 at 10:34 AM
bizjournals.com logoBreakfast Technical Briefing on Biotech Stocks -- Dynavax Technologies, Keryx Biopharma, Moleculin Biotech, and ZIOPHARM Oncology
www.bizjournals.com - October 12 at 10:35 AM
prnewswire.com logoBreakfast Technical Briefing on Biotech Stocks -- Dynavax Technologies, Keryx Biopharma, Moleculin Biotech, and ... - PR Newswire (press release)
www.prnewswire.com - October 12 at 10:35 AM
finance.yahoo.com logoZIOPHARM Oncology, Inc. breached its 50 day moving average in a Bearish Manner : ZIOP-US : October 11, 2017
finance.yahoo.com - October 11 at 9:50 AM
finance.yahoo.com logoZIOPHARM Oncology, Inc. :ZIOP-US: Earnings Analysis: Q2, 2017 By the Numbers : October 5, 2017
finance.yahoo.com - October 6 at 1:08 PM
finance.yahoo.com logoETFs with exposure to ZIOPHARM Oncology, Inc. : October 6, 2017
finance.yahoo.com - October 6 at 1:08 PM
americanbankingnews.com logoZIOPHARM Oncology Inc (ZIOP) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - September 30 at 2:46 AM
globenewswire.com logoZIOPHARM Oncology Appoints David Mauney, MD, as Executive Vice President and Chief Business Officer - GlobeNewswire (press release)
globenewswire.com - September 29 at 10:26 PM
feeds.benzinga.com logoZIOPHARM Oncology Appoints David Mauney, M.D., as Executive Vice President and Chief Business Officer
feeds.benzinga.com - September 28 at 5:43 PM
americanbankingnews.com logoZIOPHARM Oncology Inc (ZIOP) Expected to Post Quarterly Sales of $1.59 Million
www.americanbankingnews.com - September 19 at 1:40 PM
americanbankingnews.com logo-$0.13 EPS Expected for ZIOPHARM Oncology Inc (ZIOP) This Quarter
www.americanbankingnews.com - September 17 at 4:24 AM
seekingalpha.com logoZIOPHARM Oncology (ZIOP) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
seekingalpha.com - September 15 at 11:51 AM
nasdaq.com logoZIOPHARM to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
www.nasdaq.com - September 5 at 8:38 PM
globenewswire.com logoZIOPHARM to Present at the Rodman & Renshaw 19th Annual Global Investment Conference - GlobeNewswire (press release)
globenewswire.com - September 5 at 3:38 PM
finance.yahoo.com logoZIOPHARM to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
finance.yahoo.com - September 5 at 9:46 AM
americanbankingnews.com logoZIOPHARM Oncology Inc (ZIOP) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - September 5 at 2:40 AM
globenewswire.com logoZIOPHARM Oncology to Participate at Upcoming CAR-TCR Summit - GlobeNewswire (press release)
globenewswire.com - September 2 at 1:29 AM
nasdaq.com logoZIOPHARM Oncology to Participate at Upcoming CAR-TCR Summit ... - Nasdaq
www.nasdaq.com - September 1 at 11:41 AM
finance.yahoo.com logoZIOPHARM Oncology to Participate at Upcoming CAR-TCR Summit
finance.yahoo.com - September 1 at 11:41 AM
americanbankingnews.com logo Brokerages Anticipate ZIOPHARM Oncology Inc (ZIOP) Will Post Earnings of -$0.13 Per Share
www.americanbankingnews.com - August 29 at 4:20 PM
finance.yahoo.com logoZIOPHARM Oncology, Inc. breached its 50 day moving average in a Bullish Manner : ZIOP-US : August 29, 2017
finance.yahoo.com - August 29 at 10:04 AM
zacks.com logoOptions Traders Expect Huge Moves in ZIOPHARM Oncology (ZIOP) Stock
www.zacks.com - August 28 at 8:01 AM
zacks.com logoOptions Traders Expect Huge Moves in ZIOPHARM Oncology (ZIOP) Stock
www.zacks.com - August 28 at 8:01 AM
finance.yahoo.com logoZIOPHARM Oncology, Inc. – Value Analysis (NASDAQ:ZIOP) : August 19, 2017
finance.yahoo.com - August 19 at 9:08 AM
americanbankingnews.com logo-$0.13 Earnings Per Share Expected for ZIOPHARM Oncology Inc (NASDAQ:ZIOP) This Quarter
www.americanbankingnews.com - August 11 at 2:36 PM
americanbankingnews.com logoZIOPHARM Oncology Inc (ZIOP) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - August 11 at 11:08 AM
nasdaq.com logoIntrexon (XON) Q2 Loss Narrower than Expected, Revenues Miss - Nasdaq
www.nasdaq.com - August 11 at 9:25 AM
finance.yahoo.com logoZIOPHARM Oncology, Inc. breached its 50 day moving average in a Bullish Manner : ZIOP-US : August 8, 2017
finance.yahoo.com - August 8 at 8:32 AM
seekingalpha.com logoSky's The Limit For Ziopharm - Seeking Alpha
seekingalpha.com - August 4 at 10:17 AM
seekingalpha.com logoZIOPHARM Oncology's (ZIOP) CEO Laurence Cooper on Q2 2017 ... - Seeking Alpha
seekingalpha.com - August 2 at 9:02 AM
seekingalpha.com logoZIOPHARM Oncology, Inc. 2017 Q2 - Results - Earnings Call Slides
seekingalpha.com - August 1 at 8:03 AM
finance.yahoo.com logoZiopharm reports 2Q loss
finance.yahoo.com - August 1 at 8:03 AM
finance.yahoo.com logoEdited Transcript of ZIOP earnings conference call or presentation 31-Jul-17 8:30pm GMT
finance.yahoo.com - August 1 at 8:03 AM
americanbankingnews.com logoZIOPHARM Oncology Inc (NASDAQ:ZIOP) Posts Quarterly Earnings Results, Hits Expectations
www.americanbankingnews.com - July 31 at 9:10 PM
americanbankingnews.com logoHead-To-Head Survey: Otonomy (OTIC) and ZIOPHARM Oncology (ZIOP)
www.americanbankingnews.com - July 31 at 8:26 PM
americanbankingnews.com logoZIOPHARM Oncology Inc (NASDAQ:ZIOP) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - July 27 at 5:59 PM
nasdaq.com logoZIOPHARM Oncology to Host Second-Quarter 2017 Financial Results and Corporate ...
www.nasdaq.com - July 25 at 8:55 AM
americanbankingnews.com logo Brokerages Expect ZIOPHARM Oncology Inc (NASDAQ:ZIOP) Will Post Earnings of -$0.13 Per Share
www.americanbankingnews.com - July 24 at 11:06 AM
feeds.benzinga.com logoZIOPHARM Oncology to Host Second-Quarter 2017 Financial Results and Corporate Update Conference Call on July 31, 2017 at 4:30 p.m. ET
feeds.benzinga.com - July 24 at 7:38 AM
americanbankingnews.com logoZIOPHARM Oncology Inc (ZIOP) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - July 17 at 11:29 AM
zacks.com logoPfizer's Mylotarg Recommended by FDA Advisory Committee
www.zacks.com - July 13 at 11:31 AM
globenewswire.com logoZIOPHARM Oncology Announces Initiation of Stereotactic Treatment Cohort in Phase 1 Study of Ad-RTS-hIL-12 + ... - GlobeNewswire (press release)
globenewswire.com - June 30 at 2:34 AM
streetinsider.com logoZiopharm Oncology (ZIOP) Reports Initiation of Stereotactic Treatment Cohort in Phase 1 Study of Ad-RTS-hIL-12 + Veledimex in Recurrent Glioblastoma
www.streetinsider.com - June 29 at 8:15 AM
seekingalpha.com logoBullish On Ziopharm
seekingalpha.com - June 22 at 2:54 PM
feeds.benzinga.com logoMid-Afternoon Market Update: Fang Drops After Q1 Results; Invivo Therapeutics Shares Surge
feeds.benzinga.com - June 20 at 3:55 PM
seekingalpha.com logoZIOPHARM Oncology (ZIOP) Presents At Jefferies 2017 Global Healthcare Conference - Slideshow
seekingalpha.com - June 12 at 3:15 PM
streetinsider.com logoZiopharm Oncology (ZIOP) Announces Positive Updated Results of Ad-RTS-hIL-12 + Veledimex in Recurrent Glioblastoma at ASCO
www.streetinsider.com - June 6 at 3:16 AM
globenewswire.com logoZIOPHARM to Present at the Jefferies 2017 Global Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - June 2 at 8:17 AM

Social

Chart

ZIOPHARM Oncology (ZIOP) Chart for Thursday, October, 19, 2017

This page was last updated on 10/19/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.